Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CO2W
|
|||
| Drug Name |
AMG 301
|
|||
| Indication | Migraine [ICD-11: 8A80; ICD-10: G43, G43.9; ICD-9: 346] | Phase 2 | [1] | |
| Hyperprolactinaemia [ICD-11: 5A60.1; ICD-10: E22.1; ICD-9: 253.1, 346] | Investigative | [2] | ||
| Company |
Amgen Thousand Oaks, CA Novartis Pharmaceuticals East Hanover, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | PACAP type I receptor (PAC1R) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | PACAP38 and PAC1 receptor blockade: a new target for headache J Headache Pain. 2018 Aug 7;19(1):64. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.